NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.80
−1.18%Year over year
Reported trailing growth
- Revenue
- +738.8%
- EBITDA
- +236.4%
- EBIT
- +208.4%
- EPS
- +184.5%
- Free cash flow
- +253.2%
- Operating cash flow
- +264.6%
Forward estimates
Based on analyst estimates
- Revenue
- -87.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +29.5%
- EBITDA
- -38.4%
- EBIT
- -34.1%
- Net income
- -36.6%
- EPS
- -5.9%
- Free cash flow
- -44.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Aug 1, 2026